ESR1 and breast carcinoma: This phosphorylation can be further modulated by other molecules, increasing ERα DNA binding and transcriptional activity (Gao et al., 2018), thus inducing endocrine resistance in breast cancer and potentially serving as a biomarker of early resistance in ER + subtypes (Lykkesfeldt et al., 2018).